Dr. Pandey is the company’s Chief Executive Officer and also serves as Chief Scientific Officer. With more than 20 years of experience in the industry, he has played a key role in developing and guiding several Research and Development Pharmaceutical Programs at various stages. He received his doctorate in Clinical Biochemistry and conducted his postdoctoral studies at University of Montreal and at McGill University, Canada. He was a Group leader for Drug Discovery and development at Liponex Inc., Ottawa. During his tenure at Liponex Inc., Dr. Pandey played pivotal roles in bringing 2 novel molecules, through research into clinical trials, and for commercialisation for the treatment of dyslipidemia and neurodegeneration. He served as Research Scientist at University of Ottawa Heart Institute and Ottawa Hospital Research Institute (OHRI)-Neuroscience, University of Ottawa. He was Health and Safety Evaluator at the Health Canada’s Hazardous Materials Information Review Commission. He has extensive life sciences and pharma experience in the discovery, development, drug formulation, clinical trials, and commercialization of drugs. His career highlights include the development of receptor modulators for the treatment of metabolic disorders, anxiety, learning impairments, and neurodegeneration. At Medipure, Dr. Pandey is responsible for promoting leading edge research, including collaborative and interdisciplinary research in endocannabinoid-targeting prescription drug development. In addition, Dr. Pandey leads Medipure Scientific and R&D programs with his immense expertise in Pharmaceutical development of novel drugs. Dr. Pandey has received several awards and is co-author on over 50 publications, patents, medical commentaries, and scientific abstracts. He is the member of several international professional societies and serves as editorial and scientific reviewer in high-impact biomedical journals.
Dr. Nihar Pandey speaks about the Scientific research at Medipure.